BiPER Therapeutics

BiPER Therapeutics is a biotechnology and pharmaceutical startup based in France, founded in 2021. The company's slogan, "First in class small molecules pushing cancer cells to burn out," encapsulates its mission to develop a first-in-class pipeline of small molecules targeting the global metabolism of cancer. Their lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein critical in cancer modulation through the endoplasmic reticulum stress. In terms of investment, BiPER Therapeutics received a significant €500.00K debt financing investment on 14 February 2023, with Bpifrance as the primary investor. This investment is a crucial milestone for the company as it propels them forward in their mission to advance innovative cancer treatments. The company's innovative approach and focus on disrupting the cancer treatment landscape position BiPER Therapeutics as a compelling prospect for venture capital investment. With their cutting-edge small molecule therapeutics and strong investor backing, BiPER Therapeutics presents an exciting opportunity for investors looking to support groundbreaking advancements in the fight against cancer.